NEUROCRINE BIOSCIENCES INC (NBIX) Stock News

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in...

NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.

Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Deserves Consideration as a Quality Investment.

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Exhibits Quality Stock Traits. Here's Why.

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a narrative review discussing the challenges of traditional...

Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating.

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on...

Noteworthy Monday Option Activity: RBLX, COMM, NBIX

NASDAQ:NBIX: good value for what you're paying.

Investors should take notice ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—it offers a great deal for the fundamentals it presents.

Neurocrine Biosciences Stock Sees RS Rating Upgrade

Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71.

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?

The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio?

What Analysts Are Saying About Neurocrine Biosciences Stock

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced CRENESSITY™ (crinecerfont) is now commercially available in the United States....

NBIX Makes Bullish Cross Above Critical Moving Average

Neurocrine Wins FDA Approval For Genetic Disorder Drug

The company can launch within a week, says Chief Executive Kyle Gano.

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITY™ (crinecerfont)...

Neurocrine Biosciences to Participate at Investor Conferences in December

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in December. Chief Executive Officer Kyle...

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented subgroup analyses and data from the KINECT®-HD study showing the impact of...

Neurocrine Biosciences to Participate at Investor Conferences in November

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming investor conferences in November. Chief Executive Officer Kyle...

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with...

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the long-term KINECT®-4 study demonstrating tardive dyskinesia remission in...

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2024 and provided...

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and...

"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins

Motley Fool analysts Matt Argersinger and Yasser El-Shimy face off.

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study of INGREZZA®...